The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.
Satoshi Yuki
No relevant relationships to disclose
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult
Hiraku Fukushima
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Yoshimitsu Kobayashi
No relevant relationships to disclose
Kazuaki Harada
No relevant relationships to disclose
Toraji Amano
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Miki Tateyama
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Soh Saitoh
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Yasuyuki Kawamoto
No relevant relationships to disclose
Tomofumi Takagi
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Kencho Miyashita
No relevant relationships to disclose
Manabu Onodera
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck; Otsuka; Synergy International; Taiho Pharmaceutical; Yakult